Regulus is focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. Regulus uniquely combines leading biology with proprietary chemistry and bioinformatics to discover and develop microRNA therapeutics in key disease areas of high unmet medical need. Regulus leverages a mature oligonucleotide platform that has undergone decades of research and development. Regulus’ single-stranded oligonucleotides called anti-miRs target upregulated microRNAs and are able to distribute broadly in multiple tissues without the need of formulation or specialized delivery vehicle. Typically, anti-miRs are simply mixed with saline solution and delivered by subcutaneous injection. By regulating microRNA function, this new approach has allowed the ability to regulate entire networks of genes through the modulation of a single microRNA.
Watch the video
RNA-based therapeutics hold significant potential as promising treatment options for human disease.
Nature Reviews Genetices
View a poster on the Regulation of microRNA biogenesis, function, and degradation published in Nature Reviews Genetics.